Alembic Pharmaceuticals Limited — Important, 29-06-2025: Updates

Alembic Pharmaceuticals has announced a board meeting to approve the financial results for the quarter and half-year. The company secured USFDA final approval for its Doxorubicin Hydrochloride Liposome Injection (20 mg/10 mL and 50 mg/25 mL single-dose vials), entering a market estimated at US$29 million. This expands Alembic's portfolio to 224 ANDA approvals, strengthening its US generics presence and potential revenue from oncology injectables.